Clinical Trials in China / NCT06461351
Recruiting
Observational
Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection
NCT06461351 · tracked via the Priya Life Science China tracker
Condition(s) studied
B-cell Tumors
Investigational drug(s) / intervention(s)
Inaticabtagene autoleucel Injection
Inaticabtagene autoleucel Injection: Inaticabtagene autoleucel Injection
Study summary
This clinical trial adopts an observational research method to conduct annual follow-up and monitoring of patients receiving treatment with Inaticabtagene Autoleucel Injection after its commercialization, in order to evaluate the delayed adverse events of Inaticabtagene Autoleucel Injection.
Eligibility
Inclusion Criteria:
1. Agree to sign an informed consent form for long-term follow-up studies.
2. Registered clinical trial patients with different indications for this product who have received at least one infusion of Inaticabtagene Autoleucel Injection in the past, as well as post market commercialized patients.
Exclusion Criteria:
\- None.
Primary outcome measure(s)
- Replication-competent lentivirus，RCL — once a year from date of Inaticabtagene Autoleucel Injection treatment until date of death from any cause, assessed up to 15 years.
Real time quantitative polymerase chain reaction was used for detection, QPCR method.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Institute of Hematology & Blood Diseases Hospital | Tianjin | Tianjin Municipality | Recruiting |
More Juventas Cell Therapy Ltd. trials in China
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06461351 on ClinicalTrials.gov ↗ ← All trials in China